Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
70%
Prostate Cancer
70%
Castration-resistant Prostate Cancer
38%
Enzalutamide
34%
Abiraterone
26%
Androgen Receptor
24%
Overall Survival
20%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
20%
Prostate-specific Antigen
19%
Advanced Prostate Cancer
18%
Androgen Deprivation Therapy
16%
Docetaxel
15%
Bipolar Androgen Therapy
13%
Recurrent Prostate Cancer
12%
Prostate Cancer Patients
12%
PARP Inhibitor (PARPi)
11%
Progression-free Survival
11%
Circulating Tumor Cells
11%
Androgen Receptor Splice Variant 7
10%
Germ Cells
9%
Phase II Trial
9%
Tumor
8%
Hazard Ratio
8%
Sipuleucel-T
8%
Confidence Interval
8%
Chemotherapy
8%
BRCA2
8%
Androgens
8%
Clinical Trials
7%
Androgen Signaling
7%
Clinical Outcomes
7%
Nave
7%
DNA Repair Genes
6%
Gene mutation
6%
Metastasis
6%
AR-V7
6%
Abiraterone Acetate
6%
Androgen Receptor Splice Variant
5%
Prostate
5%
Oligometastatic Prostate Cancer
5%
Metastasis-free Survival
5%
Androgen Receptor Antagonist
5%
Radical Prostatectomy
5%
Radium-223
5%
Prednisone
5%
Systemic Therapy
5%
Mismatch Repair
5%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
92%
Castration Resistant Prostate Cancer
74%
Androgen
32%
Androgen Receptor
31%
Enzalutamide
29%
Abiraterone
22%
Neoplasm
19%
Overall Survival
19%
Prostate Specific Antigen
17%
Progression Free Survival
16%
Docetaxel
15%
Disease
15%
Chemotherapy
11%
Biological Marker
11%
Immunotherapy
9%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
8%
Clinical Trial
8%
Malignant Neoplasm
7%
Sipuleucel T
7%
Prostate Specific Membrane Antigen
6%
Taxane
5%
Phase II Trials
5%
Abiraterone Acetate
5%
Medicine and Dentistry
Prostate Cancer
100%
Castration Resistant Prostate Cancer
44%
Androgen Receptor
29%
Enzalutamide
18%
Prostate Specific Antigen
15%
Disease
14%
Neoplasm
14%
Metastatic Carcinoma
13%
Overall Survival
13%
Abiraterone
12%
Progression Free Survival
11%
Circulating Tumor Cell
10%
Androgen Deprivation Therapy
10%
Androgen
9%
PARP Inhibitor
9%
Radiation Therapy
9%
Biological Marker
8%
Immunotherapy
8%
DNA Repair
8%
Chemotherapy
7%
Clinical Trial
7%
Androgen Therapy
6%
Malignant Neoplasm
6%
Prostatectomy
6%
Prostate Specific Membrane Antigen
6%
Germ Cell
6%
Hazard Ratio
6%
Arm
5%
Gene Mutation
5%